Ngm Biopharmaceuticals Profit Margin

The latest profit margin for NGM is -3165.68% as of December 2023. That compares with -293.98% in the prior-year period — down 976.8% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Ngm Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, NGM's profit margin moved from -293.98% to -3165.68% — a 976.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ngm Biopharmaceuticals's valuation or profitability profile.

Against Healthcare companies, NGM currently prints -3165.68% for profit margin, while the sector average sits near 15.58%. That is roughly 20413.6% below the sector mean. Large gaps often invite a closer look at Ngm Biopharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Ngm Biopharmaceuticals converts resources into returns. At -3165.68%, NGM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -293.98% in the prior-year period — down 976.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NGM's profit margin (-3165.68%), review year-over-year change from -293.98%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.